What is the current Price Target for the Theravance Biopharma Inc stock?

The average Theravance Biopharma Inc target price is $14.50. This is 56.42% higher than the current stock price. The highest price target is 126.54%, the lowest is 7.87%. 4 Analysts have issued a price target Theravance Biopharma Inc 2026 .

How high will the Theravance Biopharma Inc stock rise?

No reliable answer can be given as to how high the Theravance Biopharma Inc stock will rise. The performance of stocks, including the Theravance Biopharma Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Theravance Biopharma Inc stock today?

The performance of Theravance Biopharma Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Theravance Biopharma Inc stock fall?

The decline in Theravance Biopharma Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Theravance Biopharma Inc Forecast, price target & analysts

$9.46

2.05% today

Nasdaq, Feb 28, 08:46 pm CET

ISIN

KYG8807B1068

Symbol

TBPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Theravance Biopharma Inc Target price 2025 - Analyst rating & recommendation

Theravance Biopharma Inc Classifications & Recommendation:

Buy

50%

Hold

50%

Theravance Biopharma Inc Price Target

Target Price	$14.50
Price	$9.27
Potential	56.42% register free of charge
Number of Estimates	4

	4 Analysts have issued a price target Theravance Biopharma Inc 2026 . The average Theravance Biopharma Inc target price is $14.50. This is 56.42% register free of charge higher than the current stock price. The highest price target is $21.00 126.54% register free of charge , the lowest is $10.00 7.87% register free of charge .
	A rating was issued by 4 analysts: 2 Analysts recommend Theravance Biopharma Inc to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Theravance Biopharma Inc stock has an average upside potential 2026 of 56.42% register free of charge . Most analysts recommend the Theravance Biopharma Inc stock at Buy or hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Revenue Million $	64.38	103.26
	12.12%	60.39%

4 Analysts have issued a sales forecast Theravance Biopharma Inc 2025 . The average Theravance Biopharma Inc sales estimate is

Unlock

. This is

Unlock

than the revenue of the last 12 months(TTM). The highest sales forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics:

2024	$64.4m	12.12%
2025	$103m 60.39% Unlock
2026	$86.7m 16.03% Unlock
2027	$108m 24.03% Unlock
2028	$158m 47.04% Unlock
2029	$242m 53.24% Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1.16	-0.18
	16.00%	84.48%
P/E		negative
EV/Sales		3.94

4 Analysts have issued a Theravance Biopharma Inc forecast for earnings per share. The average Theravance Biopharma Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1.16	16.00%
2025	$-0.18 84.48% Unlock
2026	$-1.01 461.11% Unlock
2027	$-0.58 42.57% Unlock
2028	$0.10 117.24% Unlock
2029	$1.73 1,630.00% Unlock

Current	-8.03	14.94%
2025	-50.79 532.50% Unlock
2026	-9.18 81.93% Unlock
2027	-15.89 73.09% Unlock
2028	95.90 703.52% Unlock
2029	5.37 94.40% Unlock

Based on analysts' sales estimates for 2025, the Theravance Biopharma Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

Unlock

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of

Unlock

This results in the following potential growth metrics and future valuations:

Current	6.32	5.39%
2025	3.94 37.69% Unlock
2026	4.69 19.10% Unlock
2027	3.78 19.37% Unlock
2028	2.57 32.00% Unlock
2029	1.68 34.74% Unlock

Current	7.08	13.69%
2025	4.41 37.65% Unlock
2026	5.26 19.10% Unlock
2027	4.24 19.37% Unlock
2028	2.88 31.99% Unlock
2029	1.88 34.74% Unlock

Theravance Biopharma Inc...

Current Theravance Biopharma Inc Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 27 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 25 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 16 2024

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 27 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 25 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 16 2024

Discover more stocks with a high price target

Coinbase Global, Inc. 60.51%

BioNTech SE - ADR 30.07%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now